Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia
Luzelena Caro(Merck & Co., Inc., Rahway, NJ, USA (United States)), Elizabeth G. Rhee(Merck & Co., Inc., Rahway, NJ, USA (United States)), Elaine Gadzicki(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joseph L. Kuti(Hartford Hospital), David P. Nicolau(Hartford Hospital), Zhen Zeng, Brian Yu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jan J. De Waele(Ghent University Hospital), Adedayo Adedoyin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kajal Larson(Entasis Therapeutics (United States))
Cited by 67
Related Papers
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5.1k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021
|Critical Care Medicine|2021|2.8k
Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome
|Intensive Care Medicine|2013|1.6k
Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. I. Definitions
|Intensive Care Medicine|2006|1.5k
DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
|Clinical Infectious Diseases|2014|1.1k